DIPNA PHARMACHEM LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 543594
₹4.36
▼ -0.16 (-3.54%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
67/100
Moderate
Valuation
100/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹11 Cr
PE (TTM)
Data unavailable.
Price to Book
0.2
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-51.7
Free Cash Flow
₹-18 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
1.16
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.21
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
Data unavailable.
Net Margin
8.84%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
22.44%
as of March 31, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 4 met
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.21)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 1 met
  • No 1-year return beats the industry median

Value and momentum

1 of 5 met
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.5%
Low 4.3000 · High 4.5200
1W return
-6.2%
Low 4.3000 · High 4.9500
1M return
-13.7%
Low 4.3000 · High 5.9300
52W return
-51.7%
Low 4.3000 · High 7.2000
Lifetime High ₹30.2000 (Sept. 12, 2022)
Lifetime Low ₹4.3600 (Sept. 30, 2026)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
4.5
10D
4.6
20D
4.9
50D
5.8
100D
7.2
200D
9.9

Delivery and volume

Day avg. delivery
65.5%
Week avg. delivery
64.9%
Month avg. delivery
78.4%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

4.39
Pivot
First resistance4.49
Second resistance4.61
Third resistance4.71
First support4.27
Second support4.17
Third support4.05
Day RSI35.2
Day MFI13.1
Day MACD-0.39
Day MACD signal-0.44

Beta

1M-0.79
3M-1.43
1Y-1.43
3Y0.57

Price change analysis

↓ -13.7%
Over 1 Month
LowHigh
4.305.93
↓ -51.7%
Over 3 Months
LowHigh
4.307.20
↓ -51.7%
Over 6 Months
LowHigh
4.307.20
↓ -51.7%
Over 1 Year
LowHigh
4.307.20
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (March 31, 2026)
₹2 Cr
Net profit (March 31, 2026)
₹0 Cr
Basic EPS (March 31, 2026)
₹0.0700

Ranks #176 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter9.13%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 9.13% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
14 Aug 2026 HRIDAY AATISH SHAH Bulk Buy 150,000 5.7000 BSE
4 Aug 2026 SANJAY NIRMAL JAIN HUF Bulk Sell 273,000 4.3900 BSE
4 Aug 2026 NEERITA SANJAY JAIN Bulk Sell 297,000 4.1000 BSE
27 Jul 2026 NAMITA HEMANT JAIN Bulk Sell 177,000 4.2500 BSE
7 Jul 2026 NAMITA HEMANT JAIN Bulk Sell 156,000 5.5500 BSE
1 Jul 2026 HEMANT NARESH JAIN HUF Bulk Sell 132,000 5.8900 BSE
26 May 2026 HEMANT NARESH JAIN HUF Bulk Sell 144,000 7.2200 BSE
21 Nov 2025 KALPALABDHI SECURITIES PRIVATE LIMITED Bulk Sell 237,000 16.8900 BSE
21 Nov 2025 NAMITA HEMANT JAIN Bulk Buy 240,000 16.8600 BSE
20 Nov 2025 KALPALABDHI SECURITIES PRIVATE LIMITED Bulk Sell 324,000 15.5100 BSE

All bulk and block deals →

Corporate Announcements

All 1 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Insider Trading / SAST Dipna Pharmachem Ltd - 543594 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.21)

Weaknesses

Data unavailable.

Opportunities

  • Trading below book value (PB 0.18)

Threats

  • Down 51.7% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about DIPNA PHARMACHEM LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.